A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT07083011
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor) — DRUG
    68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan

Study Details

The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)

Key Dates

Start date
Nov 1, 2025
Status verified
Apr 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
35 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Obese subjects with HFpEF (heart failure with preserved ejection fraction)
  • Active Comparator: Active cardiac sarcoidosis
  • Active Comparator: Healthy subjects

Primary Outcome Measure

Myocardial 68Ga-FAPI (68Ga-Fibroblast Activation Protein Inhibitor) volume [ Time Frame: Baseline and 6 Months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905
Amyloid Research Team
(507) 266-4426
Omar Abou Ezzeddine, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies